A Phase 1 interventional study of [14C]-AZD4205, single 50 mg oral dose administrated on day 1 in Healthy Volunteers, sponsored by Dizal Pharmaceuticals. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-24.
Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase I, open label, healthy volunteers, ADME study with single oral administration of [14C]-AZD4205.
Phase I study to evaluate the excretion of AZD4205 radioactive dose, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C]-AZD4205 in healthy male volunteers. The purpose of this study is to investigate ADME properties of AZD4205 by analyzing blood, urine and feces collected during the study
Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of \[14C\]-AZD4205
Drug: [14C]-AZD4205, single 50 mg oral dose administrated on day 1
Drug page: Golidocitinib
Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
Percentage of radioactive dose recovered in urine and faeces and total percentage
To evaluate the percentage of radioactive dose of \[14C\] radiolabelled AZD4205 recovered in urine, feces, and in total
Time frame: Up to 57 days
Provide samples for subsequent studies
Provide samples for subsequent studies to characterize the metabolism of \[14C\]AZD4205
Time frame: Up to 57 days
AUC(0-inf) for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting AUC(0-inf)
Time frame: Up to 57 days
AUC(0-t) for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting AUC(0-t)
Time frame: Up to 57 days
Cmax for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting Cmax
Time frame: Up to 57 days
tmax for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting tmax
Time frame: Up to 57 days
tlag for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting tlag
Time frame: Up to 57 days
t1/2 for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting t1/2
Time frame: Up to 57 days
λz for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting λz
Time frame: Up to 57 days
CL/F for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting CL/F
Time frame: Up to 57 days
Vss/F for [14C] radioactivity in plasma and whole blood
To determine AZD4205 plasma concentrations and the resulting Vss/F
Time frame: Up to 57 days
Distribution of total radioactivity in blood
To compare disposition of drug-related total radioactivity in whole blood to that in plasma
Time frame: Up to 57 days
Number of participants with treatment-related adverse events, and serious adverse events
To assess the safety and tolerability of a single dose of AZD4205 in healthy adult male subjects.
Time frame: Up to 57 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Mar 2020, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Golidocitinib